Toxic and metabolic dementias
Katie Osborn
Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Search for more papers by this authorKatie Osborn
Geisel School of Medicine at Dartmouth, Hanover, NH, USA
Search for more papers by this authorMichael D. Geschwind MD PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCaroline Racine Belkoura PhD
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSummary
Toxic and metabolic forms of dementia (TMD) are critical to identify as they are often treatable, if not curable, unlike most other dementias. This chapter first discusses toxic causes of dementia, followed by a review of major metabolic etiologies of cognitive impairment. It then focuses on three agents, namely carbon monoxide, ethanol and lead that are among the most common causes of toxic cognitive dysfunction. Cognitive impairment might be a direct consequence of medical illness or metabolic perturbations. For patients with potential endocrine disease, and liver or kidney failure, certain blood tests are essential to rule out metabolic causes for dementia. A variety of hormone abnormalities have been linked to cognitive impairment or dementia. The chapter also focuses on three common metabolic issues that have been shown to cause dementia: thyroid dysregulation, hepatic dysfunction, and disorders of glucose metabolism.
References
- Prockop LD, Rowland LP: Occupational and environmental neurotoxicology. In: Merritt's Neurology. 12 edn. Edited by LP Rowland, TA Pedley. Philadelphia: Lippincott Williams & Wilkins; 2010: 1174–1200.
- Ernst A, Zibrak JD: Carbon monoxide poisoning. New England Journal of Medicine 1998, 339(22): 1603–1608.
- Prockop LD: Carbon monoxide brain toxicity: Clinical, magnetic resonance imaging, magnetic resonance spectroscopy, and neuropsychological effects in 9 people. Journal of Neuroimaging 2005, 15: 144–149.
- Tomaszewski C: Carbon monoxide. In: Goldfrank's Toxicologic Emergencies. 7 edn. Edited by LR Goldfrank, NE Flomenbaum, NA Lewis, MA Howland, RS Hoffman, LS Nelson. New York: McGraw-Hill; 2002: 1478–1497.
-
Prockop LD: Carbon monoxide. In: Clinical Neurotoxicology. Edited by MR Dobbs. Philadelphia: Saunders/Elsevier; 2009: 500–514.
10.1016/B978-032305260-3.50051-4 Google Scholar
- Chang KH, Han MH, Kim HS, Wie BA, Han MC: Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter lesions. Radiology 1992, 184(1): 117–122.
- Seger D, Welch L: Carbon monoxide controversies: Neuropsychological testing, mechanism of toxicity and hyperbaric oxygen. Annals of Emergency Medicine 1994, 24: 242–248.
- Chang CC, Chang WN, Lui CC, Wang JJ, Chen CF, Lee YC, Chen SS, Lin YT, Huang CW, Chen C: Longitudinal study of carbon monoxide intoxication by diffusion tensor imaging with neuropsychiatric correlation. Journal of Psychiatry & Neuroscience 2010, 35(2): 115–125.
- Hopkins RO, Weaver LK: Carbon monoxide controversies: Neuropsychologic testing, mechanisms of toxicity, and hyperbaric oxygen. Annals of Emergency Medicine 1995, 25: 272–273.
- Crocker P: Carbon monoxide poisoning—The clinical entity an its treatment: A review. Military Medicine 1984, 149: 257–259.
- Kelley JS, Sophocleus GJ: Retinal hemorrhages in subacute carbon monoxide poisoning. Exposures in homes with blocked furnace flues. Journal of the American Medical Association 1978, 239(15): 1515–1517.
-
Myers RA, DeFazio A, Kelly MP: Chronic carbon monoxide exposure: A clinical syndrome detected by neuropsychological tests. Journal of Clinical Psychology 1998, 54(5): 555–567.
10.1002/(SICI)1097-4679(199808)54:5<555::AID-JCLP1>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- Min SK: A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta Psychiatrica Scandinavica 1986, 73(1): 80–86.
-
Raphael JC, Elkharrat D, Jars-Guincestre MC, Chastang C, Chasles V, Vercken JB, Gajdos P: Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet 1989, 19(2): 414–419.
10.1016/S0140-6736(89)90592-8 Google Scholar
- Gorman DF, Clayton D, Gilligan JE, Webb RK: A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital. Anaesthesia & Intensive Care 1992, 20(3): 311–316.
- Weaver LK, Hopkins RO, Chan KJ, Churchill S, Elliott G, Clemmer TP, Orme JF, Thomas FO, Morris AH: Hyperbaric oxygen for acute carbon monoxide poisoning. New England Journal of Medicine 2002, 347: 1057–1067.
- Amitai Y, Zlotogorski Z, Golan-Katzav V, Wexler A, Gross D: Neuropsychological impairment from acute low-level exposure to carbon monoxide. Archives of Neurology 1988, 55(6): 845–848.
-
Murata S, Asaba H, Naritomi H, Hiraishi K, Sakai T: Magnetic resonance imaging findings on carbon monoxide intoxication. Journal of Neuroimaging 1993, 3(2): 128–131.
10.1111/jon199332128 Google Scholar
- Tom T, Abedon S, Clark RI, Wong W: Neuroimaging characteristics in carbon monoxide toxicity. Journal of Neuroimaging 1996, 6: 161–166.
- Prockop LD, Nardu KA: Brain CT and MRI findings after carbon monoxide toxicity. Journal of Neuroimaging 1999, 9: 175–181.
- Bronstein A, Clower JH, Iqbal S, Yip FY, Martin CA, Chang A, Wolkin AF, Bell J: Carbon monoxide exposures—United States, 2000–2009. Center for Disease Control (CDC) Morbidity and Mortality Weekly Report (MMWR) 2011, 60(30): 1014–1017.
- Miro O, Casodemont J, Marrientos A, Urban-Marquez A, Candellach F: Mitochondrial cytochrome c oxide inhibition during acute carbon monoxide poisoning. Pharmacology & Toxicology 1998, 82(4): 199–202.
- Lapresle J, Fardeau M: The central nervous system and carbon monoxide poisoning. II. Anatomical study of brain lesions following intoxication with carbon monoxide (22 cases). Progress in Brain Research 1967, 24: 31–74.
- Elkharrat D: Indications of normobaric and hyperbaric oxygen therapy in acute CO intoxication. In: Proceedings satellite meeting IUTOX. Dijon, France: VIIIth International Congress of Toxicology; 1998.
- Tibbles PM, Edelsberg JS: Hyperbaric-oxygen therapy. New England Journal of Medicine 1996, 334: 1642–1648.
- Van Meter KW, Weiss L, Harch PG, Andrews LC, Simanonok JP, Staab PK, Gottlieb SF: Should the pressure be off or on with use of oxygen in the treatment of carbon monoxide poisoned patients? Annals of Emergency Medicine 1994, 24(2): 283–288.
- Thom SR, Taber RI, Mediguren II, Clark JM, Hardy KR, Fisher AB: Delayed neuropsychological sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Annals of Emergency Medicine 1995, 25: 479–486.
- Weaver LK, Hopkins RO, Larson-Lorh V, Howe S, Haberstock D: Double blind, controlled, prospective, randomized clinical trial (RCT) in patients with acute carbon monoxide (CO) poisoning: Outcome of patients tested with normobaric oxygen or hyperbaric oxygen (HBO2), an interim report. Undersea & Hyperbaric Medicine 1995, 22: 14.
- Tibbles PM, Perotta PL: Treatment of carbon monoxide poisoning: A critical review of human outcome studies comparing normobaric oxygen with hyperbaric oxygen. Annals of Emergency Medicine 1994, 24: 269–276.
- Rourke SB, Grant I: The neurobehavioral correlates of alcoholism. In: Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. 3 edn. Edited by I Grant, KM Adams. New York: Oxford University Press; 2009: 398–454.
- Brust JCM: Alcoholism. In: Merritt's Neurology. 12 edn. Edited by LP Rowland, TA Pedley. Philadelphia: Lippincott Williams & Wilkins; 2010: 1076–1084.
- Sullivan EV, Fama R, Rosenbloom MJ, Pfefferbaum A: A profile of neuropsychological deficits in alcoholic women. Neuropsychology 2002, 16(1): 74–83.
- Sullivan EV, Rosenbloom MJ, Pfefferbaum A: Pattern of motor and cognitive deficits in detoxified alcoholic men. Alcoholism, Clinical and Experimental Research 2000, 24(5): 611–621.
- O'Connor PG: Alcohol. In: Merck Manual. Whitehouse, Station: Merck Sharp & Dohme Corp.; 2015, http://www.merckmanuals.com/professional/special-subjects/drug-use-and-dependence/alcohol. Accessed September 10, 2015.
- Brust JCM: Ethanol and cognition: Indirect effects, neurotoxicity and neuroprotection: A review. International Journal of Environmental Research in Public Health 2010, 7(4): 1540–1557.
- Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A, Breteler MMB: Alcohol consumption and risk of dementia: The Rotterdam study. The Lancet 2002, 359(9303): 281–286.
- Collins MA, Neafsey EJ, Mukamal KJ, Gray MO, Parks DA, Das DK, Korthuis RJ: Alcohol in moderation, cardioprotection, and neuroprotection: Epidemiological considerations and mechanistic studies. Alcoholism, Clinical and Experimental Research 2009, 33(2): 206–219.
- Gupta A, Warner J: Alcohol-related dementia: A 21st-century silent epidemic? The British Journal of Psychiatry 2008, 193(5): 351–353.
- Harper C, Kril J, Daly J: Are we drinking our neurones away? British Medical Journal (Clinical Research Ed.) 1987, 294(6571): 534–536.
- Bergman H, Borg S, Hindmarsh T, Idestrom CM, Mutzell S: Computed tomography of the brain and neuropsychological assessment of male alcoholic patients and a random sample from the general male population. Acta Psychiatrica Scandinavica Supplementum 1980, 286: 77–88.
- Carlen PL, Wilkinson DA, Wortzman G, Holgate R: Partially reversible cerebral atrophy and functional improvement in recently abstinent alcoholics. Canadian Journal of Neurological Sciences 1984, 11(4): 441–446.
- Carlen PL, Wortzman G, Holgate R, Wilkinson DA, Rankin JC: Reversible cerebral atrophy in recently abstinent chronic alcoholics measured by computed tomography scans. Science 1978, 200(4345): 1076–1078.
- Neumann T, Spies C: Use of biomarkers for alcohol use disorders in clinical practice. Addiction 2003, 98(Suppl 2): 81–91.
- Rainio J, De Giorgio F, Bortolotti F, Tagliaro F: Objective post-mortem diagnosis of chronic alcohol abuse: A review of studies on new markers. Legal Medicine (Tokyo) 2008, 10(5): 229–235.
- Harper C, Matsumoto I: Ethanol and brain damage. Current Opinion in Pharmacology 2005, 5(1): 73–78.
- Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annual Review of Medicine 1998, 49: 173–184.
- Chandler LJ, Newsom H, Sumners C, Crews F: Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons. Journal of Neurochemistry 1993, 60: 1578–1581.
- Gotz ME, Janetsky B, Pohli S, Gottschalk A, Gsell W, Tatschner T, Ransmayr G, Leblhuber F, Gerlach M, Reichmann H et al: Chronic alcohol consumption and cerebral indices of oxidative stress: Is there a link? Alcoholism, Clinical and Experimental Research 2001, 25: 717–725.
- Harper C: The neuropathology of alcohol-specific brain damage, or does alcohol damage the brain? Journal of Neuropathology and Experimental Neurology 1998, 57(2): 101–110.
- Harper C, Dixon G, Sheedy D, Garrick T: Neuropathological alterations in alcoholic brains. Studies arising from the New South Wales tissue resource centre. Progress in Neuropsychopharmacology and Biological Psychiatry 2003, 27(6): 951–961.
- Harper C, Kril J: Corpus callosal thickness in alcoholics. British Journal of Addiction 1988, 83: 577–580.
- Torvik A: Brain lesions in alcoholics: Neuropathological observations. Acta Medica Scandinavica 1987, 717: 47–54.
- Torvik A, Lindboe CF, Rogde S: Brain lesions in alcoholics: A neuropathological study with clinical correlations. Journal of the Neurological Sciences 1982, 56: 233–248.
- White RF, Janulewicz PA: Neuropsychological, neurological, and neuropsychiatric correlates of exposure to metals. In: Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. Edited by I Grant, KM Adams. New York: Oxford University Press; 2009: 350–365.
- Hanninen H: Behavioral effects of occupational exposure to mercury and lead. Acta Neurologica Scandinavica 1982, 92: 167–175.
- Pasternak G, Becker CE, Lash A, Bowler R, Estrin WJ, Law D: Cross-sectional neurotoxicology study of lead-exposed cohort. Journal of Toxicology Clinical Toxicology 1989, 27(1–2): 37–51.
- Barth A, Schaffer AW, Osterode W, Winker R, Konnaris C, Valic E, Wolf C, Rudiger HW: Reduced cognitive abilities in lead-exposed men. International Archives of Occupational and Environmental Health 2002, 75(6): 394–398.
- Jarup L: Hazards of heavy metal contamination. British Medical Bulletin 2003, 68(1): 167–182.
- Feldman RG: Occupational and Environmental Neurotoxicology. Philadelphia: Lippincott-Raven Publishers; 1999.
- Rosin A: The long-term consequences of exposure to lead. The Israel Medical Association Journal 2009, 11(11): 689–694.
- Wright RO, Tsaih SW, Schwartz J, Spiro III A, McDonald K, Weiss ST, Hu H: Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology 2003, 14(6): 713–718.
- Weisskopf MG, Wright RO, Schwartz J, Spiro III A, Sparrow D, Aro A, Hu H: Cumulative lead exposure and prospective change in cognition among elderly men: The VA normative aging study. American Journal of Epidemiology 2004, 160(12): 1184–1193.
- Khalil N, Morrow LA, Needleman H, Talbott EO, Wilson JW, Cauley JA: Association of cumulative lead and neurocognitive function in an occupational cohort. Neuropsychology 2009, 23(1): 10–19.
- Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, Links JM, Todd AC: Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology 2001, 56(2): 283.
- Poklis A, Burkett CD: Gasoline sniffing: A review. Clinical Toxicology 1977, 11(1): 35–41.
- Shih RA, Glass TA, Bandeen-Roche K, Carlson MC, Bolla KI, Todd AC, Schwartz BS: Environmental lead exposure and cognitive function in community-dwelling older adults. Neurology 2006, 67(9): 1556–1562.
- Carpenter DO, Nevin R: Environmental causes of violence. Physiology and Behavior 2010, 99(2): 260–268.
- Mason LH, Harp JP, Han DY: Pb neurotoxicity: Neuropsychological effects of lead toxicity. BioMed Research International 2014, 2014: 8 pages.
- Rabinowitz MB: Toxicokinetics of bone lead. Environmental Health Perspectives 1991, 91: 33–37.
- Nemsadze K, Sanikidze T, Ratiani L, Gabunia L, Sharashenidze T: Mechanics of lead-induced poisoning. Georgian Medical News 2009, 172–173: 92–96.
- Environmental Protection Agency EPA: Air Quality for Lead. Washington, DC: Office of Research and Development, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office; 1986.
- Gover RA: Results of lead research: Prenatal exposure and neurological consequences. Environmental Health Perspectives 1996, 104(10): 1050–1054.
- Oh RC, Brown DL: Vitamin B12 Deficiency. American Family Physician 2003, 67(5): 979–986.
- Sloan JL, Johnston JJ, Manoli I, Chandler RJ, Krause C, Carrillo-Carrasco N, . . . Venditti, CP: Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria. Nature Genetics 2011, 43(9): 883–886.
- Boxer AL, Kramer JH, Johnston K, Goldman J, Finley R, Miller BL: Executive dysfunction in hyperhomocysteinemia responds to homocysteine-lowering treatment. Neurology 2005, 64(8): 1431–1434.
- Lezak M: Metabolic and endocrine disorders. In: Neuropsychological Assessment. Volume, 3 edn. Edited by MD Lezak. New York: Oxford University Press; 1995: 274–276.
- Hershman JM: Overview of the thyroid gland. In: Merck Manual. Whitehouse Station: Merck Sharp & Dohme Corp.; 2015, http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/thyroid-disorders/hyperthyroidism. Accessed September 10, 2015.
- Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Roliński J: Immune disorders in Hashimoto's thyroiditis: What do we know so far? Journal of Immunology Research 2015, 2015: 979167.
- Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA et al: Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the American Thyroid Association and American Association of clinical endocrinologists. Endocrinology Practice 2011, 17(3): 456–520.
- Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J: A psychiatric and neuropsychological study of patients with untreated Graves’ disease. General Hospital Psychiatry 1988, 10(1): 49–55.
- Revuelta GJ, Weiner WJ, Factor SA: Hyperkinetic movement disorders. In: Neurology for the Non-Neurologist. 6 edn. Edited by WJ Weiner, CG Goetz, RK Shin, SL Lewis. Philadelphia: Lippincott Williams & Wilkins; 2010: 241–286.
- Vogel A, Elberling TV, Hording M, Dock J, Rasmussen AK, Feldt-Rasmussen U, Perrild H, Waldermar G: Affective symptoms and cognitive functions in the acute phase of Graves’ thyrotoxicosis. Psychoneuroendocrinology 2007, 32(1): 36–43.
- Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, Wiersinga WM: Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. European Journal of Endocrinology 2005, 153(6): 747–753.
- Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG: Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. Journal of Clinical Endocrinology and Metabolism 2006, 91(1): 145–153.
- Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange Jr. AJ: A survey study of neuropsychiatric complaints in patients with Graves’ disease. Journal of Neuropsychiatry and Clinical Neuroscience 1996, 8(2): 181–185.
- Stern RA, Prange Jr. AJ: Neuropsychiatric aspects of endocrine disorders. In: Comprehensive Textbook of Psychiatry. Volume 1, 6 edn. Edited by HI Kaplan, BJ Saddock. Baltimore: Williams & Wilkins; 1995: 241–251.
- Somerville JG, Tremont G, Stern RA: The Boston qualitative scoring system as a measure of executive functioning in Rey-Osterrieth complex figure performance. Journal of Clinical and Experimental Neuropsychology 2000, 22(5): 613–621.
- Bhatara VS, Tripathi RP, Sankar R, Gupta A, Khushu S: Frontal lobe proton magnetic-resonance spectroscopy in Graves’ disease: A pilot study. Psychoneuroendocrinology 1998, 23(6): 605–612.
- Tremont G, Stern RA, Westervelt HJ, Bishop CL, Davis JD: Neurobehavioral functioning in thyroid disorders. Medicine and Health Rhode Island 2003, 86(10): 318–322.
- Constant EL, de Volder AG, Ivanoiu A, Boi A, Labar D, Seghers A, Cosnard G, Melin J, Daumerie C: Cerebral blood flow and glucose metabolism in hypothyroidism: A positron emission tomography study. Journal of Clinical Endocrinology and Metabolism 2001, 86(8): 3864–3870.
- Kinuya S, Michigishi T, Tonami N, Aburano T, Tsuji S, Hashimoto T: Reversible cerebral hypoperfusion observed with Tc-99 m HMPAO SPECT in reversible dementia caused by hypothyroidism. Clinical Nuclear Medicine 1999, 24(9): 666–668.
- Fukui T, Hasegawa Y, Takenaka H: Hyperthyroid dementia: Clinicoradiological findings and response to treatment. Journal of Neurosurgical Sciences 2001, 184(1): 81–88.
- Dugbartey A: Neurocognitive aspects of hypothyroidism. Journal of the American Medical Association 1998, 158(13): 1413–1418.
- Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodes J: Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of Hepatology 1999, 30(5): 890–895.
- Steward CA, Malinchoc M, Kim WR, Kamath PS: Hepatic encephalopathy as a predictor of survival in patients with end-state liver disease. Liver Transplantation 2007, 13(10): 1366–1371.
- Garg H, Kumar A, Garg P, Sharma B, Sharma C, Sarin SK: Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Digestive and Liver Disease 2012, 44(2): 166–171.
- Detry O, DeRoover A, Honore P, Meurisse M: Brain edema and intracranial hypertension in fulminant hepatic failure: Pathophysiology and management. World Journal of Gastroenterology 2006, 12(46): 7405–7412.
- Fichet J, Mercier E, Genee O, Garot D, Legras A, Dequin PF: Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. Journal of Critical Care 2009, 24(3): 364–370.
- Prakash R, Muller KD: Mechanisms, diagnosis and management of hepatic encephalopathy. National Review of Gastroenterology and Hepatology 2010, 7(9): 515–525.
- Li YY, Nie YQ, Sha WH, Zeng Z, Yang FY, Ping L, Jia L: Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World Journal of Gastroenterology 2004, 10(16): 2397–2401.
- Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, Ravdin LD, Romero-Gomez M, Stracciari A, Weissenborn K et al: Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver International 2009, 29(5): 629–635.
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT: Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3): 716–721.
-
Poordad FF: The burden of hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2007, 25(1): 3–9.
10.1111/j.1746-6342.2006.03215.x Google Scholar
- Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R: Lactulose improves cognitive functions and health related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45: 549–559.
- Sherlock S, Summerskill WHJ, White RF, Phear EA: Portal-systemic encephalopathy: Neurological complications of liver disease. Lancet 1954, 2: 453–457.
- Amodio P, Montagnese S, Gatta A, Morgan MY: Characteristics of minimal hepatic encephalopathy. Metabolic brain disease 2004, 19(3–4): 253–267.
- Zeegen R, Drinkwater JE, Dawson AM: Method for measuring cerebral dysfunction in patients with liver disease. British Medical Journal 1970, 2: 633–636.
- Elithorn A, Lunzer M, Weinman J: Cognitive deficits associated with chronic hepatic encephalopathy and their response to levodopa. Journal of Neurology, Neurosurgery, and Psychiatry 1975, 38: 794–798.
- Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO, McClain CJ: Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Archives of Internal Medicine 1980, 140: 519–521.
- Hegedus A, Tarter RE, Van Thiel DH, Schade RR, Gavaler JS, Starzl TE: Neuropsychiatric characteristics associated with primary biliary cirrhosis. International Journal of Psychiatry in Medicine 1984, 14(4): 303–314.
- Rikkers L, Jenko P, Rudman D, Friedes D: Subclinical hepatic encephalopathy: Detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978, 75: 462–469.
- Tarter RE, Hegedus AM, Van Thiel DH, Schade RS, Gavaler JS, Starzl TE: Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 1984, 86: 1421–1427.
- McCrea M, Cordoba J, Vessey G, Blei AT, Randolph C: Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Archives of Neurology 1996, 53: 758–763.
- Schomerus H: Differential diagnosis of acute cerebral disorders in alcoholism and cirrhosis. Internist (Berl) 1981, 22(9): 555–561.
- Cordoba J, Raguer N, Flavia M, Vargas V, Jacas C, Rovira AJ: T2 hyperintensity along the corticospinal tract in cirrhosis relates to functional abnormalities. Hepatology 2003, 38: 1026–1033.
- Shawcross D, Jalan R: The pathophysiologic basis of hepatic encephalopathy: Central role for ammonia and inflammation. Cellular and Molecular Life Sciences 2005, 62: 2295–2304.
- Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD: Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001, 358: 38–39.
- Forton DM, Thomas HC, Murphey CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD: Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002, 35: 433–439.
- Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, Wrba F, Madl C, Gangl A, Ferenci P: Subclinical impairment of brain function in chronic hepatitis C infection. Journal of Hepatology 2002, 37: 349–354.
- Hilsabeck R, Perry W, Hassanein TI: Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002, 35(2): 440–446.
- Hilsabeck R, Hassanein TI, Carlson MC, Ziegler EA, Perry W: Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. Journal of the International Neuropsychological Society 2003, 9: 847–854.
- McAndrews MP, Farcnik K, Carlen PL, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ: Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005, 41: 801–808.
- Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok ASF, Padmanabhan L, The HALT-C Trial Group A: Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. Journal of Hepatology 2005, 43: 614–622.
- Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ: Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychosomatic Research 2000, 49(5): 311–317.
- Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster S: Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. American Journal of Gastroenterology 2001, 96(1): 170–178.
- Johnson ME, Fisher DG, Fenaughty A, Theno SA: Hepatitis C virus and depression in drug users. American Journal of Gastroenterology 1998, 93(5): 785–789.
- Rovira AJ, Alonso J, Cordoba J: MR imaging findings in hepatic encephalopathy. American Journal of Neuroradiology 2008, 29: 1612–1621.
- Fitz JG: Hepatic encephalopathy, hepatopulmonary syndromes, hepatorenal syndrome, coagulopathy, and endocrine complications of liver disease. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 7 edn. Edited by M Feldman, LS Friedman, MH Sleisenger. Philadelphia: Saunders; 2002: 1543–1565.
- Butterworth RF: Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. Journal of Clinical and Experimental Hepatology 2015, 5(Suppl 1): S96–S103.
- Mladenović D, Hrnčić D, Petronijević N, Jevtić G, Radosavljević T, Rašić-Marković A, Puškaš N, Maksić N, Stanojlović O: Finasteride improves motor, EEG, and cellular changes in rat brain in thioacetamide-induced hepatic encephalopathy. American Journal of Physiology. Gastrointestinal and Liver Physiology 2014, 307(9): G931–940.
- Kobtan AA, El-Kalla FS, Soliman HH, Zakaria SS, Goda MA: Higher grades and repeated recurrence of hepatic encephalopathy may be related to high serum manganese levels. Biological Trace Element Research 2015, DOI: 10.1007/s12011-015-0405-5, Online ISSN: 1559–0720.
- Palomero-Gallagher N, Zilles K: Neurotransmitter receptor alterations in hepatic encephalopathy: A review. Archives of Biochemistry and Biophysics 2013, 536(2): 109–121.
- Foster KJ, Lin S, Turck CJ: Current and emerging strategies for treating hepatic encephalopathy. Critical Care Nursing Clinics of North America 2010, 22(3): 341–350.
- Liou IW: Diagnosis and management of hepatic encephalopathy. Hepatitis C Online 2013.
- American Diabetes Association A: Diagnosis and classification of diabetes mellitus. Diabetes Care 2005, 28: S37–S42.
- American Diabetes Association A: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002, 25: 213–229.
- Wilkinson DA, Prockop LD: Hypoglycemia: Effect on the nervous system. In: Handbook of Clinical Neurology. Volume 27, Metabolic and Deficiency Diseases of the Nervous System, Edited by PJ Vinken, GW Bruyn. Amsterdam: North Holland Publishing Co.; 1976: 53–78.
- Whitmer RA, Kerter AJ, Yaffe K, Quesenberry Jr. CP, Selby JV: Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. Journal of the American Medical Association 2009, 301(15): 1565–1572.
- Buckingham B, Wilson DM, Lecher T, Hanas R, Kaiserman K, Cameron F: Duration of nocturnal hypoglycemia before seizures. Diabetes Care 2008, 31(11): 2110–2112.
- Messier C: Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiology of Aging 2005, 265: S26–S30.
- Korf ESC, White RF, Scheltens P, Launer LJ: Brain aging in very old men with type 2 diabetes. Diabetes Care 2006, 29: 2268–2271.
- Decker DA, Royter V, Paletz L, Roberts P, Mirocha J, Waters M: Strict glycemic control improves functional outcomes in ischemic stroke. Unpublished data 2010.
- Mazighi M, Amerenco P: Hyperglycemia: A predictor of poor prognosis in acute stroke. Diabetes & Metabolism 2001, 27(6): 718–720.
- Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM: Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Annals of Neurology 2002, 52(1): 20–28.
- Ahmed N, Davalos A, Erikson N, Ford GA, Glahn J, Hennerici M, Mikulik R, Kaste M, Lees KR, Lindsberg PJ et al: Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis. Archives of Neurology 2010, 67(2): 1123–1130.
- Whitman RA, Kanter AJ, Yaffe K, Quesenberry Jr. CP, Selby JV: Hypoglycemic episodes and the risk of dementia in older people with type 2 diabetes mellitus. Journal of the American Medical Association 2009, 101(15): 1565–1572.
- Aremza Z, Fidelman Z, Berner YN, Adunsky A: Infection related hypoglycemia in institutionalized demented patients. Archives of Gerontology and Geriatrics 2007, 45: 191–200.
- Miles WR, Root HF: Psychological tests applied in diabetic patients. Archives of Internal Medicine 1922, 30: 767–777.
- Dreary IJ, Crawford JR, Hepburn DA, Langan SJ, Blackmore LM, Frier BM: Severe hypoglycemia and intelligence in adult patients with insulin-treated diabetes. Diabetes 1993, 42: 341–344.
- Cukierman T, Gerstein HC, Williamson JD: Cognitive decline and dementia in diabetes—Systematic overview of prospective observational studies. Diabetologia 2005, 48(12): 2460–2469.
- Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf PA: NIDDM and blood pressure as risk factors for poor cognitive performance. Francophone Studies Diabetes Care 1997, 20(9): 1388–1395.
-
Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2 edn. Hillsdale: Erlbaum; 1988.
10.1046/j.1526-4610.2001.111006343.x Google Scholar
- Brands AMA, Kessels RPC: Diabetes and the brain: Cognitive performance in Type 1 and Type 2 diabetes. In: Neuropsychological Assessment of Neuropsychiatric and Neuromedical Disorders. 3 edn. Edited by I Grant, KM Adams. New York: Oxford University Press; 2009: 350–365.
- Tiehuis AM, van der Graaf Y, Visseren FL, Vincken KL, Biessels GJ, Appelman APA, Kappelle J, Mali WPTM, SMART Study Group A: Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008, 39: 1600–1603.
- Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ: Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 2005, 28(6): 1431–1437.
- Lobnig BM, Kromeke O, Optenhostert-Porst C, Wolf OT: Hippocampal volume and cognitive performance in longstanding Type 1 diabetic patients without macrovascular complications. Diabetic Medicine 2006, 23: 32–39.
- Lunetta M, Damanti AR, Fabbri G, Lombardo M, Di Mauro M, Mughini L: Evidence by magnetic resonance imaging of cerebral alterations of atrophy type in young insulin-dependent diabetic patients. Journal of Endocrinological Investigation 1994, 17: 241–245.
- Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM: Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006, 55: 326–333.
- DCCT Research Group A: Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Annals of Internal Medicine 1996, 124: 379–388.
- Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003, 348: 383–393.
- Reichard P, Rosenqvist U: Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy. Journal of Internal Medicine 1989, 226: 81–87.
- Schurr A, Payne RS, Miller JJ, Tseng MT: Preischemic hyperglycemia-aggravated damage: Evidence that lactate utilization is beneficial and glucose-induced corticosterone release is detrimental. Journal of Neuroscience Research 2001, 1(66): 782–789.
- Gentile NT, Seftchick MW, Huynh T, Kruus LK, Gaughan J: Decreased mortality by normalizing blood glucose after acute ischemic stroke. Academic Emergency Medicine 2006, 13(2): 174–180.